A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms

Description

This study is being conducted to assess the Safety, Tolerability, and Pharmacokinetics of INCB160058 in Participants With Myeloproliferative Neoplasms.

Trial Eligibility

Inclusion Criteria: * Age ≥ 18 years * Participants with intermediate-1 or higher risk PMF, post-PV, of post-ET MF, histologically confirmed * Evidence of minimum burden of disease based on symptoms and/or splenomegaly * Life expectancy \> 6 months * Willingness to undergo a pretreatment and regular on-study bone marrow biopsies and aspirations (as appropriate to disease) * Existing documentation of JAK2V617F mutation from a qualified local laboratory * Previously treated with at least 1 JAK inhibitor for ≥ 12 weeks and resistant, refractory, intolerant to, or have lost response to JAK inhibitor treatment Exclusion Criteria: * Presence of a hematological malignancy requiring treatment, other than PMF, post-PV MF, or post-ET MF * Prior history of major bleeding or thrombosis within the 3 months prior to study enrollment * Participants with abnormal hematologic, hepatic, or renal function based on laboratory evaluation * Has undergone prior allogenic or autologous stem-cell transplantation or allogenic stem-cell transplantation is planned * Active invasive malignancy * Significant concurrent, uncontrolled medical condition * Active HBV/HCV or known HIV * Any prior MF-directed therapy within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment * Participants undergoing treatment with G-CSF or GM-CSF, romiplostim, or eltrombopag at any time within 4 weeks before the first dose of study treatment Other protocol-defined Inclusion/Exclusion Criteria may apply.

Study Info

Interventions

Locations Recruiting

Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.